退行性二尖瓣修复可恢复预期寿命
本研究回顾性分析1011例2003–2017年间因退行性二尖瓣反流接受孤立二尖瓣修复的患者,采用参数分布分析比较其长期生存与美国普通人群预期寿命。结果显示,在40至89岁任何年龄手术的患者,其修复后预期寿命与普通人群匹配;20–39岁组死亡少、预测受限,但生存亦似正常。结论提示退行性二尖瓣修复可使患者预期寿命恢复至普通人群水平,但需更大样本更长随访验证,尤其年轻患者。
要点
- 退行性二尖瓣反流行孤立修复后,40–89岁患者预期寿命与普通美国人群匹配。
- 20–39岁组死亡事件少,预测受限,但生存亦似正常。
- 研究支持对退行性二尖瓣病变积极修复,但需更大样本更长随访验证。
核心结论
- 退行性二尖瓣修复可使患者预期寿命恢复至普通美国人群水平,且不限于手术年龄。
研究设计与样本
- 回顾性研究纳入1011例2003–2017年间因退行性二尖瓣反流接受孤立二尖瓣修复的患者。
- 采用参数分布分析长期术后死亡数据,Weibull概率图经Anderson-Darling拟合优度检验为最佳拟合分布。
- 按年龄每10岁分组(范围20–89岁),用估计分布的置信区间比较术后额外预期寿命与普通美国人群。
主要发现
- 二尖瓣修复后患者预期寿命在40至89岁任何年龄与普通美国人群匹配。
- 额外预期寿命的单侧95%置信区间下限与普通人群相应中位额外预期寿命无显著差异。
- 20–39岁组死亡事件少,限制预测性,但生存亦似正常。
临床怎么用
- 对退行性二尖瓣反流患者,二尖瓣修复可望使预期寿命恢复至普通人群水平,支持积极手术修复。
局限性
- 回顾性研究设计。
- 20–39岁组死亡事件少,限制预测性。
- 需更大样本、更长随访研究验证,尤其年轻患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mitral valve repair (MVr) for severe, degenerative mitral regurgitation is the gold standard, because medical management carries poor prognosis. However, despite clear benefit of MVr, many eligible patients are untreated. This study investigated whether MVr restores patients to normal life expectancy, at any age of operation, by comparing long-term survival of patients after MVr with the life expectancy of the general United States population. METHODS: This retrospective study investigated 1011 patients with degenerative mitral regurgitation who underwent isolated MVr between 2003 and 2017. Parametric distribution analysis was applied to long-term post-MVr mortality data, and Weibull probability plots provided the best-fit distribution by Anderson-Darling Goodness-of-Fit testing. Confidence intervals of the estimated distribution were used to compare additional life expectancy after MVr to the general US population across multiple decades of life. Patients after MVr were categorized by age into decade (range, 20-89 years). RESULTS: The life expectancy of patients after MVr matched the life expectancy of the general US population at any age between 40 and 89 years. Lower-bound one-sided 95% confidence intervals for additional life expectancy were not appreciably different from corresponding median additional life expectancy of the general population. There were few deaths in the 20- to 39-year-old group, limiting predictability, but survival also appeared normative. CONCLUSIONS: These findings suggest that degenerative MVr restores anticipated life expectancy to that of the general population, regardless of age. Although our findings underscore the importance of repair for degenerative mitral disease, larger studies with longer term follow-up are needed to reinforce this finding, particularly for younger patients.
引用
- Watt TMF, Brescia AA, Murray SL, et al. Degenerative Mitral Valve Repair Restores Life Expectancy. Ann Thorac Surg. 2019. PMID: 31472142. doi:10.1016/j.athoracsur.2019.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。